tirzepatide study near me — CRL Tirzepatide for Medical Weight Loss

94% reduction in progression from pre diabetes to type 2 diabetes with tirzepatide.** **Based on a three-year clinical trial study (176-week treatment period) sponsored by Eli Lilly and Company, weekly injections of tirzepatide significantly reduced the risk of progression to type 2 diabetes by 94% in adults with prediabetes who were overweight or obese compared to placebo

You use your benefits card at checkout, and the funds come straight out of your account

[DOI] [PubMed] [Google Scholar] 199.Ringseis R, Wege N, Wen G, Rauer C, Hirche F, Kluge H, et al

10.1038/nature11111 [DOI] [PMC free article] [PubMed] [Google Scholar] Grecksch G., Bartzsch K., Widera A., Becker A., Hollt V., Koch T